Meenakshi Bewtra, MD, PhD, MPH
Associate Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
Attending Physician, Penn Medicine at Radnor
Attending Physician, Corporal Michael J. Crescenz Veteran's Affairs Medical Center
Attending Physician, Hospital of the University of Pennsylvania
Co-Section Head & Research and Education Director for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, University of Pennsylvania
Department: Medicine
Contact information
423 Guardian Drive
724 Blockley Hall
Philadelphia, PA 19104
724 Blockley Hall
Philadelphia, PA 19104
Office: 215-746-4922
Publications
Links
Search PubMed for articles
Penn Medicine Inflammatory Bowel Disease Program
The Undergraduate Clinical Scholars Program is an epidemiology and biostatistics summer research enrichment program with research mentoring, with a goal of fostering strong research interests and durable mentoring relationships in human clinical research.
University of Pennsylvania Perelman School of Medicine Center for Clinical Epidemiology and Biostatistics (CCEB)
Penn Medicine at Radnor
The IBD-Immunology Initiative (I3) is a prospective biobank enrolling all inflammatory bowel disease patients (IBD) at UPenn. The I3 has collaborators within Penn, nationally and internationally in academia, private foundations and industry.
I am an active science, research and public health advocate.
Search PubMed for articles
Penn Medicine Inflammatory Bowel Disease Program
The Undergraduate Clinical Scholars Program is an epidemiology and biostatistics summer research enrichment program with research mentoring, with a goal of fostering strong research interests and durable mentoring relationships in human clinical research.
University of Pennsylvania Perelman School of Medicine Center for Clinical Epidemiology and Biostatistics (CCEB)
Penn Medicine at Radnor
The IBD-Immunology Initiative (I3) is a prospective biobank enrolling all inflammatory bowel disease patients (IBD) at UPenn. The I3 has collaborators within Penn, nationally and internationally in academia, private foundations and industry.
I am an active science, research and public health advocate.
Education:
BSc
Yale University, New Haven, CT, 1998.
MD
University of Pennsylvania, Philadelphia, PA, 2003.
MPH
Harvard University School of Public Health, Boston, MA, 2003.
PhD (Epidemiology)
University of Pennsylvania, 2013.
Permanent linkBSc
Yale University, New Haven, CT, 1998.
MD
University of Pennsylvania, Philadelphia, PA, 2003.
MPH
Harvard University School of Public Health, Boston, MA, 2003.
PhD (Epidemiology)
University of Pennsylvania, 2013.
Description of Clinical Expertise
Inflammatory bowel disease; ulcerative colitis; Crohn's disease; immune-mediated colitis; microscopic colitisDescription of Research Expertise
Epidemiology; Real-World Data; Discrete Choice Experiment; Clinical TrialsSelected Publications
Mayer LS, Arnold J, Roettele F, Reuter N, Pattekar A, Ohtani T, Ribeiro MM, Siwicki R, Bruder K, Obwegs D, Stahl E, Buechel S, Roehlen N, Kolter J, Mansoori Moghadam Z, Alaswad A, Zhumalidova Z, Li G, Liu X, Li Y, Singh A, Villacorta Hidalgo J, Paraskevopoulou MD, Yajnik V, Juarez J, Ren Y, Li H, Wherry EJ, Lewis JD, Wu GD, Bewtra M, Tomov VT, Thimme R, Bengsch B, Hasselblatt P, Picelli S, Hofmann M, Sagar.: Single-cell profiling reveals diverse γδ T cell subsets in ulcerative colitis. Sci Immunol 11: eadx8474, Feb 2026.Karakasheva TA, Martinez CM, Zhou Y, Qui J, Chen XE, Soto GE, Nettleford SK, Hix OT, Roach DM, Laguerta AM, Thadi A, Edwards RM, Aleynick D, Weinbrom S, Borodyanskaya E, Pickering OH, Fulton M, Chen CH, Peterson IV, Hagen EB, Yannuzzi IP, Haider Z, Cramer Z, Conrad MA, Li N, Bewtra M, Uzun Y, Tan K, Kelsen JR, Minn AJ, Lengner CJ, Hamilton KE.: An Epigenetic Basis for Sustained Inflammatory Epithelial Progenitor Cell States in Crohn's Disease. Cell Mol Gastroenterol Hepatol 20: 101665, Oct 2025.
Mayer AS, Xiao R, Grossman A, Bewtra M, George MD, Weiss PF.: Temporal Trends in and Associations With Nonsteroidal Anti-inflammatory Drug Prescription in Adult and Pediatric Patients With Inflammatory Bowel Disease. Arthritis Care Res (Hoboken) Sep 2025.
Yang H, Dungan M, Beyries K, Wang X, Kilpatrick R, Chen B, Oh S, Berkowitz M, Smith D, Koralov SB, Axelrad J, Lengner CJ, Belle N, Bewtra M, Katona BW, Cadwell K.: MAIT cell enrichment in Lynch syndrome is associated with immune surveillance and colorectal cancer risk. bioRxiv Aug 2025.
Cao S, Nguyen KM, Ma K, Tan T, Yao X, Liu TC, Ayoub M, Devi J, Samaan S, Liu Y, Smith R, Silviera ML, Hunt SR, Wise PE, Mutch MG, Glasgow SC, Chapman WC Jr, Cowan ML, Ciorba MA, Colonna M, Deepak P; SPARC IBD Investigators.: Revealing hyperactivated IFN-γ pathways in perianal fistulizing Crohn's disease using single-cell and spatial multi-omics. J Clin Invest 135: e193413, Jul 2025.
Bewtra, Meenakshi; Schreiber, Stefan; Buisson, Anthony; Hur, Peter; Panattoni, Laura; Hauber, Brett; Gahlon, Grace; Coulter, Josh; Smith, Christina; Guo, Xiang; Land, Natalie; Wosik, Karolina; Cappelleri, Joseph; Maravic, Melissa Culhane; Walsh, Alissa : Comparing the benefit-risk tradeoffs advanced therapy naïve vs experienced patients are willing to accept when selecting advanced therapy for moderate-to-severe ulcerative colitis: A discrete choice experiment in the United States and Europe. Digestive Disease Week, San Diego CA May 2025.
Regueiro MD, Bewtra M, Dubinsky MC, Branquinho D, Feng C, McDonnell A, Gianfrancesco MA.: Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States. Inflamm Bowel Dis Apr 2025.
Kruger AJ, Dormont F, Capit N, Schilsky S, Roberts A, Lin Y, Badalamenti S, Wiekowski M, Bewtra M, Colombel JF.: Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis/Crohn's Disease: A Retrospective Study. Clin Gastroenterol Hepatol Apr 2025.
Bewtra M: "Attacks on Science" Stand Up For Science, Philadelphia Rally March 2025.
Yang JC, Janssen EM, Wallace MJ, Sheahan A, Lynch J, Bewtra M, Marko M, Johnson FR, Bozzi LM.: Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease. Am J Gastroenterol 120: 2848-2856, Mar 2025.